Skip to main content

Advertisement

SpringerLink
Log in

Novel antiretroviral agents in HIV therapy

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

There are many promising new agents in development for the treatment of HIV type 1 (HIV-1). The targets of antiretroviral drugs include the three major HIV-1 enzymes (reverse transcriptase, protease, and integrase), final packaging and export of mature virions, and entry mediated by the CD4 receptor and the CCR5 and CXCR4 coreceptors. Drugs in development in existing classes are primarily designed to provide new options for those with resistance to existing agents. Novel agents such as those targeting integrase, entry inhibitors, and those targeting viral processing likely will be useful the treatment of antiretroviral-experienced patients. Depending on safety, efficacy, tolerability, and convenience of dosing, new agents may also alter the current treatment paradigms for first-line therapy. This review summarizes data on several drugs that could move forward into the clinical arena and affect the lives of those infected with HIV-1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Panel on Clinical Practices for Treatment of HIV Infection:. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://AIDSinfo.nih.gov. Accessed August 9, 2006. One of the premiere up-to-date resources on current management of HIV-1-infected individuals.

  2. Kaufmann D, Pantaleo G, Sudre P, et al.: CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998, 351:723–724.

    Article  PubMed  CAS  Google Scholar 

  3. Struble K, Murray J, Cheng B, et al.: Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS 2005, 19:747–756.

    Article  PubMed  Google Scholar 

  4. Bethell R: Antiviral activity of SPD754 against clinical isolates of HIV-1 resistant to other NRTIs. Presented at the 12th International HIV Drug Resistance Workshop. Cabo San Lucas, Mexico; June 10–14, 2003.

  5. Gu Z, Allard B, de Muys JM, et al.: In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob Agents Chemother 2006, 50:625–631.

    Article  PubMed  CAS  Google Scholar 

  6. Bethell R, De Rooj ER, Smolders KGM, et al.: Comparison of the in vitro mitochondrial toxicity of SPD754 in HepG2 cells with nine other nucleoside reverse transcriptase inhibitors. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2004. Washington, DC; October 30–November 2, 2004.

  7. Cahn P, Lange J, Cassetti I, et al.: Anti HIV-1 activity of SPD754, a new NRTI: results of a 10 day monotherapy study in treatment naive HIV patients. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–17, 2003.

  8. Bethell RC, Collins P: Genotypic and phenotypic analysis of HIV-1 isolates from patients after 10 days monotherapy with SPD 754. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 30–November 2, 2004.

  9. Collins P, Shiveley L, Anderson C, Bethell R: Analysis of the genotypes of viruses isolated from patients after 10 days monotherapy with SPD754. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  10. Hazen R, St Clair M, Hanlon M, et al.: GW0385: A broad spectrum, ultrapotent inhibitor of wild-type and protease-inhibitor-resistant HIV-1. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–16, 2003.

  11. De Meyer S, Azijn H, Surleraux D, et al.: TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005, 49:2314–2321.

    Article  PubMed  CAS  Google Scholar 

  12. Arasteh K, Clumeck N, Pozniak A, et al.: TMC114/ ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS 2005, 19:943–947. Summarizes results from a pivotal study that demonstrated the utility of TMC-114 (darunavir) given with ritonavir in patients with PI-resistant virus. This data led to the phase 2b trials submitted to the FDA, which recently led to approval of darunavir.

    Article  PubMed  CAS  Google Scholar 

  13. Katlama C, Berger D, Bellos N, et al.: Efficacy of TMC114/ r in 3-Class Experienced Patients with Limited Treatment Options: 24-Week Planned Interim Analysis of 2 96-week Multinational Dose-finding Trials. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  14. Molina JM, Cohen C, Katlama C, et al.: POWER 3 trial: 24-week efficacy and safety results of TMC114/r in treatment- experienced patients. Presented at the 12th Annual Conference of British HIV Association. Brighton, UK; March 29–April 1, 2006.

  15. Pozniak A, Saag M, Bellos N, et al.: Efficacy of TMC114/r in treatment-experienced patients: factors infiuencing outcome in the pooled 24-week analysis of POWER 1, 2 and 3. Presented at the 12th Annual Conference of British HIV Association. Brighton, UK; March 29–April 1, 2006.

  16. Ford SL, Reddy YS, Anderson MT, et al.: Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 2006, 50:2201–2206.

    Article  PubMed  CAS  Google Scholar 

  17. Ward D, Lalezari J, Thompson M, et al.: Preliminary antiviral activity and safety of 640385/ritonavir in HIVinfected patients (study HPR10006): an 8-week interim analysis. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 16–19, 2005.

  18. Ford SL, Shelton MJ, Murray SC, et al.: A study to investigate the interaction between 640385/ritonavir (640385/r) and tenofovir (TDF) in healthy subjects. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 16–19, 2005.

  19. Gruzdev B, Rakhmanova A, Doubovskaya E, et al.: A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003, 17:2487–2494.

    Article  PubMed  CAS  Google Scholar 

  20. Sankatsing SU, Weverling GJ, Peeters M, et al.: TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 2003, 17:2623–2627.

    Article  PubMed  CAS  Google Scholar 

  21. Gazzard BG, Pozniak AL, Rosenbaum W, et al.: An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003, 17:F49–54.

    Article  PubMed  CAS  Google Scholar 

  22. Montaner J, Domingo P, Junod P, et al.: Safety and tolerability of TMC125 in 3-class-experienced HIV-infected patients: 24-week primary analysis of trial TMC 125-C203. Presented at the Tenth European AIDS Conference/European AIDS Clinical Society. Dublin, Ireland; November 17–20, 2005.

  23. Nadler J, Grossman HA, Hicks C, et al.: Efficacy and tolerability of TMC125 in HIV patients with NNRI and PI resistance at 24 weeks: TMC125-C223. Presented at the Tenth European AIDS Conference/European AIDS Clinical Society. Dublin, Ireland; November 17–20, 2005.

  24. de Bethune M-P, Andries K, Azijn H, et al.: TMC-278, a new potent NNRTI, with an increased barrier to resistance and good pharmacokinetic profile. 12th Conference on Retroviruses and Opportunistic Infections 2005. Boston, MA; February 22–25, 2005.

  25. Goebel F, Yakovlev A, Pozniak A, et al.: TMC-278: Potent anti-HIV activity in antiretroviral therapy-naïve patients. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  26. Zhang XQ, Sorensen M, Fung M, Schooley RT: Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother 2006, 50:2231–2233.

    Article  PubMed  CAS  Google Scholar 

  27. Moore JP, Sattentau QJ, Klasse PJ, Burkly LC: A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992, 66:4784–4793.

    PubMed  CAS  Google Scholar 

  28. Kuritzkes DR, Jacobson J, Powderly WG, et al.: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004, 189:286–291. Clinical data demonstrating the antiviral activity of a monoclonal antibody that acts by binding to CD4 molecules.

    Article  PubMed  CAS  Google Scholar 

  29. Reimann KA, Khunkhun R, Lin W, et al.: A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus. AIDS Res Hum Retroviruses 2002, 18:747–755.

    Article  PubMed  CAS  Google Scholar 

  30. Norris D, Morales J, Gathe J, et al.: TNX-355 in combination with optimized background regimen (OBR) exhibits greater antiviral activity than OBR alone in HIV treatment experienced patients. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 16–19, 2005.

  31. Moore JP, Kitchen SG, Pugach P, Zack JA: The CCR5 and CXCR4 coreceptors—central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004, 20:111–126. A comprehensive review of HIV-1 tropism and its implications for pathogenesis and treatment.

    Article  PubMed  CAS  Google Scholar 

  32. Daar ES, Lynn HS, Donfield SM, et al.: Stromal cell-derived factor-1 genotype, co-receptor tropism and human immunode ficiency virus type 1 progression. J Infect Dis 2005, 192:1597–1605.

    Article  PubMed  Google Scholar 

  33. Brumme ZL, Goodrich J, Mayer HB, et al.: Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005, 192:466–474. Summarizes the epidemiology of HIV-1 tropism in a cohort of antiretroviral- naïve subjects. This work may help define the population that may be the initial targets for CCR5 inhibitor therapy.

    Article  PubMed  CAS  Google Scholar 

  34. Wilkin T, Su Z, Kuritzkes D, et al.: Co-receptor tropism in patients screening for ACTG 5211, a phase 2 study of vicriviroc, a CCR5 inhibitor. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  35. Schols D, Claes S, Hatse S, et al.: Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist. Presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; Febryary 10–14, 2003.

  36. Stone N, Dunaway S, Flexner C, et al.: Biologic activity of an orally bioavailable CXCR4 antagonist in human subjects. Presented at the 15th International AIDS Conference. Bangkok, Thailand; July 11–16, 2004.

  37. Strizki JM, Tremblay C, Xu S, et al.: Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunode- ficiency virus type 1. Antimicrob Agents Chemother 2005, 49:4911–4919.

    Article  PubMed  CAS  Google Scholar 

  38. Schurmann D, Rouzier R, Nougarede R, et al.: SCH D: antiviral activity of a CCR5 receptor antagonist. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  39. Greaves W, Landovitz R, Fatkenheuer G, et al.: Late virologic breakthrough in treatment-naive patients on a regimen of combivir + vicriviroc. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  40. Schering-Plough: Schering Plough provides update on phase II study of vicriviroc [press release]. http://www. schering-plough.com/schering_plough/news/release. jsp?releaseID=826957. Accessed August 22, 2006.

  41. Dorr P, Westby M, Dobbs S, et al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721–4732.

    Article  PubMed  CAS  Google Scholar 

  42. Fatkenheuer G, Pozniak AL, Johnson MA, et al.: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005, 11:1170–1172. A study that demonstrated the in vivo potency of maraviroc, a novel CCR5 antagonist.

    Article  PubMed  CAS  Google Scholar 

  43. Westby M, Lewis M, Whitcomb J, et al.: Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006, 80:4909–4920. Describes the mechanism by which X4 virus emerged in subjects treated with maraviroc. This study demonstrated that X4 did not emerge as a result of a switch in the tropism of the R5 populations, but rather selection for pre-existing X4 strains.

    Article  PubMed  CAS  Google Scholar 

  44. Morales-Ramirez J, Teppler H, Kovacs C, et al.: Antiviretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in ART-naïve HIV-infected patients. Presented at the Tenth European AIDS Conference/European AIDS Clinical Society. Dublin, Ireland; November 17–20, 2005.

  45. Grinsztejn B, Nguyen BY, Katlama C, et al.: Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Presented at the 13th Conference on Retroviruses and Opportunistic Infections 2006. Denver, CO; February 5–8, 2006.

  46. Sato M, Motomura T, Aramaki H, et al.: Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006, 49:1506–11508.

    Article  PubMed  CAS  Google Scholar 

  47. Matsuzaki Y, Watanabe W, Yamataka K, et al.: JTK-303/ GS 9137, a novel small-molecule inhibitor of HIV-1 integrase: Anti-HIV activity profile and pharmacokinetics in animals. Presented at the 13th Conference on Retroviruses and Opportunistic Infections 2006. Denver, CO; February 5–8, 2006.

  48. De Jesus E, Berger D, Markowitz M, et al.: The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naive and experienced patients. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  49. Li F, Goila-Gaur R, Salzwedel K, et al.: PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 2003, 100:13555–13560.

    Article  PubMed  CAS  Google Scholar 

  50. Martin D, Jacobson J, Schurmann D, et al.: PA-457, the first-in-class maturation inhibitor, exhibits antiviral activity following a single oral dose in HIV-1-infected patients. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  51. Beatty G, Lalezari J, Eron J, et al.: Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 16–19, 2005.

Download references

Author information

Authors and Affiliations

  1. Division of HIV Medicine, Harbor-UCLA Medical Center, 1124 West Carson Street, N-24, 90502, Torrance, CA, USA

    Eric S. Daar MD

Authors
  1. Caitlin Reed MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric S. Daar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric S. Daar MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reed, C., Daar, E.S. Novel antiretroviral agents in HIV therapy. Curr Infect Dis Rep 8, 489–496 (2006). https://doi.org/10.1007/s11908-006-0024-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-006-0024-6

Keywords

Search

Navigation